Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials DOI Creative Commons
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 540 - 540

Published: Feb. 21, 2025

Background/Objectives: While positive symptoms of schizophrenia are often satisfactorily controlled, negative difficult to treat, persisting despite treatment. Different strategies have been devised deal with this problem. We aimed review drug treatment for in controlled trials marketed drugs. Methods: searched the PubMed database and resulting records’ reference lists identify eligible using schizophrenia[ti] AND “negative symptom*”[ti] as a search strategy. determined eligibility through Delphi rounds among all authors. Results: On 11 February 2025, we identified 1485 records on 3 more from lists. Eligible were 95 records. Most studies double-blind, randomized trials, carried-out add-on patients stabilized antipsychotics. Other antipsychotics most frequent comparators, followed by antidepressants, recently, antioxidants gaining importance trials. Many especially those conducted Western world, found no significant effects compared placebo, while Iranian positive, although not strong effect size. Conclusions: Current research has contributed little progress schizophrenia. The reason might reside absence knowledge mechanisms whereby these generated, which prevents us designing possibly effective strategies, and/or chronicity symptoms, they first be established even when do become fully apparent.

Language: Английский

Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention DOI Creative Commons
Yafen Wang, Weicheng Meng, Zhixin Liu

et al.

Frontiers in Cellular Neuroscience, Journal Year: 2022, Volume and Issue: 16

Published: Nov. 2, 2022

Psychiatric diseases, such as schizophrenia, bipolar disorder, autism spectrum and major depressive place a huge health burden on society. Cognitive impairment is one of the core characteristics psychiatric disorders vital determinant social function disease recurrence in patients. This review thus aims to explore underlying molecular mechanisms cognitive identify valuable biomarkers for diagnosis, treatment prevention

Language: Английский

Citations

19
A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy DOI Creative Commons

Zude Chen,

Xiaoshuang Yang,

Zugen Chen

et al.

BMC Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Oct. 25, 2023

Abstract Background Prostate cancer (PCa) is the most common malignancy diagnosed in men. Immune checkpoint blockade (ICB) alone showed disappointing results PCa. It partly due to formation of immunosuppressive tumor microenvironment (TME) could not be reversed effectively by ICB alone. Methods We used PCa cell lines evaluate combined effects CN133 and anti-PD-1 subcutaneous osseous mice models, as well underlying mechanisms. Results found that reduce infiltration polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), combination with augment antitumor allograft models. However, failed elicit an anti-tumor response bone metastatic mice. Mechanistically, inhibit PMN-MDSCs TME soft tissues downregulation gene expression PMN-MDSC recruitment but change involved activation co-treatment group relative model. Conclusions Taken together, our work firstly demonstrated therapy may increase therapeutic efficacy reactivation positive immune tissue

Language: Английский

Citations

10
A method for HDAC activity screening in postmortem human brain. A proof-of-concept study with antipsychotics DOI Creative Commons

Oihane Martínez-Peula,

Alfredo Ramos‐Miguel, Carolina Muguruza

et al.

Journal of Neuroscience Methods, Journal Year: 2025, Volume and Issue: unknown, P. 110365 - 110365

Published: Jan. 1, 2025

Language: Английский

Citations

0
Chemoproteomics Sheds Light on Epigenetic Targets of [11C]Martinostat in the Human Brain DOI
Mary C. Catanese, Yvonne E. Klingl, Tonya M. Gilbert

et al.

ACS Chemical Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 6, 2025

Initiation of research programs to investigate binding specificity based on in vivo positron emission tomography (PET) imaging results can provide rich opportunities improve data interpretation, gain biological insight, and inform hypothesis development. Here, we profile the neuroepigenetic probe, [11C]Martinostat. In neuroimaging studies using [11C]Martinostat have uncovered differential regional uptake relation age sex patients with schizophrenia, bipolar disorder, Alzheimer's disease, low-back pain compared healthy controls. Previous recombinant proteins thermal shift assays postmortem tissue indicate that engages class I putatively IIb histone deacetylases (HDACs). While HDACs serve multiple functions, including regulation chromatin remodeling gene transcription, it is not known how differences HDAC expression may arise across brain regions. functionally interact a diverse array multisubunit complexes, engagement associated partners contribute these differences. To further assess target [11C]Martinostat, designed synthetic probe inhibitor structural scaffold for use competition experiments followed by proteomic analysis tissue. The called Compound 4, appears paralog HDAC2 HDAC6 robust manner. We also unique interacting partners, synaptic from synaptotagmin (SYT) family neuronal pentraxin 2 (NPTX2). Further work associations regions human needed better understand dysregulation psychiatric neurological conditions.

Language: Английский

Citations

0
Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials DOI Creative Commons
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 540 - 540

Published: Feb. 21, 2025

Background/Objectives: While positive symptoms of schizophrenia are often satisfactorily controlled, negative difficult to treat, persisting despite treatment. Different strategies have been devised deal with this problem. We aimed review drug treatment for in controlled trials marketed drugs. Methods: searched the PubMed database and resulting records’ reference lists identify eligible using schizophrenia[ti] AND “negative symptom*”[ti] as a search strategy. determined eligibility through Delphi rounds among all authors. Results: On 11 February 2025, we identified 1485 records on 3 more from lists. Eligible were 95 records. Most studies double-blind, randomized trials, carried-out add-on patients stabilized antipsychotics. Other antipsychotics most frequent comparators, followed by antidepressants, recently, antioxidants gaining importance trials. Many especially those conducted Western world, found no significant effects compared placebo, while Iranian positive, although not strong effect size. Conclusions: Current research has contributed little progress schizophrenia. The reason might reside absence knowledge mechanisms whereby these generated, which prevents us designing possibly effective strategies, and/or chronicity symptoms, they first be established even when do become fully apparent.

Language: Английский

Citations

0